Supplementary Fig. S2 from Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

Cristiana Sessa,Patricia Lorusso,Anthony Tolcher,Françoise Farace,Nathalie Lassau,Angelo Delmonte, Antonio Braghetti,Rastislav Bahleda,Patrick Cohen,Marie Hospitel,Christine Veyrat-Follet,Jean-Charles Soria

crossref（2023）

引用 0|浏览14

暂无评分

摘要

Supplementary Fig. S2 - PDF file 123K, Change in Fridericia-corrected QT interval from baseline vs ombrabulin (A) and RPR258063 (B) concentrations as the predictor

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要